Join our mailing list to receive the latest updates and alerts Flag Subscribe

Fredrikson & Byron acted as legal counsel to Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses, in a licensing agreement that will allow AstraZeneca’s global biologics research and development arm, MedImmune, to develop and, if successful, to commercialize Omnis’s lead oncolytic virus program. Fredrikson’s legal team included Ann M. Ladd and Ryan C. Brauer.

Read the news release.

Jump to Page

Fredrikson & Byron, P.A. stores cookies on your device to enhance site navigation, make your browsing experience as useful as possible, and analyze site usage. By accessing this website with cookies enabled in your web browser, you agree to the storing of cookies on your device. Please read our Privacy Policy and our Disclaimer.